---
title: "Lakefront Biotherapeutics H1 FY26 net sales drop 87% to EUR 18.6 million; operating loss narrows 54% to EUR 107.2 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295443360.md"
description: "Lakefront Biotherapeutics reported H1 FY26 results with net sales dropping 87% to EUR 18.6 million, while the operating loss narrowed 54% to EUR 107.2 million. The company posted a net profit of EUR 16.6 million, reversing previous losses. R&D and SG&A expenses decreased significantly. Cash reserves stood at EUR 2.24 billion. Key developments include the closure of the Ouro Medicines acquisition with Gilead and FDA Fast Track and orphan status for gamgertamig in AIHA and ITP."
datetime: "2026-08-10T20:04:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295443360.md)
  - [en](https://longbridge.com/en/news/295443360.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295443360.md)
---

# Lakefront Biotherapeutics H1 FY26 net sales drop 87% to EUR 18.6 million; operating loss narrows 54% to EUR 107.2 million

-   Lakefront Biotherapeutics posted a net profit of €16.6 million, swinging from a loss, while operating loss narrowed 54% to €107.2 million. \* Total net sales fell 87% to €18.6 million, with collaboration revenue down 96% to €4.5 million. \* R&D expenses dropped 80% to €56.5 million, while SG&A declined 22% to €58 million. \* Cash, cash equivalents and financial investments totaled €2.24 billion at June 30; the group kept its end-2026 liquidity outlook at €1.98 billion-€2.05 billion. \* Ouro Medicines acquisition with Gilead closed; gamgertamig gained FDA Fast Track and orphan status in AIHA and ITP, with registrational studies expected in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakefront Biotherapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608101601OMX\_\_\_**EUPR**NL\_GNW1001256930\_nl) on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [LKFT.US](https://longbridge.com/en/quote/LKFT.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)

## Related News & Research

- [GSA Capital Partners LLP Takes Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296193567.md)
- [Grandfield & Dodd LLC Makes New Investment in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296196164.md)
- [Confluence Wealth Services Inc. Acquires 7,986 Shares of Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/295901632.md)
- [ABN Amro Investment Solutions Has $32.39 Million Stock Holdings in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/295894826.md)
- [Thomasville National Bank Purchases New Shares in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/295783241.md)